A large, observational study of common gout treatment allopurinol shows less than half of patients reach recommended treatment goal

(Edelman Public Relations) AstraZeneca and Ardea Biosciences today presented results from a large study of allopurinol, a treatment commonly used to lower uric acid in patients with gout. The LASSO (Long-term Allopurinol Safety Study evaluating Outcomes in gout patients) study was a multinational, six-month, open, prospective observational study involving 1,735 patients with gout and was designed to evaluate the safety and efficacy of medically appropriate doses of allopurinol.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news